Inhibition of hepatitis C virus production by aptamers against the core protein

Journal of Virology

Volumn 88, Issue 4, 2014, Pages 1990-1999

  Shi, Shali ^a   Yu, Xiaoyan ^a   Gao, Yimin ^a   Xue, Binbin ^a   Wu, Xinjiao ^a   Wang, Xiaohong ^a   Yang, Darong ^a   Zhu, Haizhen ^a,b  

^a HUNAN UNIVERSITY   (China)

^b Central South University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; BLOTTING, WESTERN; CELL LINE; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE LIBRARY; HEPACIVIRUS; HUMANS; IMMUNOPRECIPITATION; MICE; PLASMIDS; PROTEIN BINDING; REAL-TIME POLYMERASE CHAIN REACTION; SELEX APTAMER TECHNIQUE; VIRAL CORE PROTEINS; VIRION;

EID: 84893490750     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03312-13     Document Type: Article

References (33)

1. Lavanchy D. 2009. The global burden of hepatitis C. Liver Int. 29(Suppl 1):74-81. http://dx.doi.org/10.1111/j.1478-3231.2008.01934.x.
2. Gaudy C, Thevenas C, Tichet J, Mariotte N, Goudeau A, Dubois F. 2005. Usefulness of the hepatitisCvirus core antigen assay for screening of a population undergoing routine medical checkup. J. Clin. Microbiol. 43:1722-1726. http://dx.doi.org/10.1128/JCM.43.4.1722-1726.2005.
3. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, Hezode C, Picchio G, Dhumeaux D, Neumann AU, McHutchison JG, Pawlotsky JM. 2002. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 36:211-218. http://dx.doi.org/10.1053/jhep.2002.34130.
4. Rice CM. 2011. New insights into HCV replication: potential antiviral targets. Top. Antivir. Med. 19:117-120. http://www.iasusa.org/sites/default/files/tam/19-3-117.pdf.
5. Yi M, Ma Y, Yates J, Lemon SM. 2009. Trans-complementation of an NS2 defect in a late step in hepatitis C virus (HCV) particle assembly and maturation. PLoS Pathog. 5:e1000403. http://dx.doi.org/10.1371/journal.ppat.1000403.
6. Cerutti A, Maillard P, Minisini R, Vidalain PO, Roohvand F, Pecheur EI, Pirisi M, Budkowska A. 2011. Identification of a functional, CRM-1-dependent nuclear export signal in hepatitis C virus core protein. PLoS One 6:e25854. http://dx.doi.org/10.1371/journal.pone.0025854.
7. Shi Q, Jiang J, Luo G. 2013. Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes. J. Virol. 87:6866-6875. http://dx.doi.org/10.1128/JVI.03475-12.
8. Strosberg AD, Kota S, Akahashi TV, Snyder JK, Mousseau G. 2010. Core as a novel viral target for hepatitis C drugs. Virus 2:1734-1751. http://dx.doi.org/10.3390/v2081734.
9. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. http://dx.doi.org/10.1126/science.1114016.
10. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami N, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796. http://dx.doi.org/10.1038/nm1268.
11. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U.S.A. 102:9294-9299. http://dx.doi.org/10.1073/pnas.0503596102.
12. Ellington AD, Szostak JW. 1990. In vitro selection of RNA molecules that binds specific ligands. Nature 346:818-822. http://dx.doi.org/10.1038/346818a0.
13. Tuerk C, Gold L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510. http://dx.doi.org/10.1126/science.2200121.
14. Keefe AD, Pai S, Ellington A. 2010. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9:537-550. http://dx.doi.org/10.1038/nrd3141.
15. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. 2002. High permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76:13001-13014. http://dx.doi.org/10.1128/JVI.76.24.13001-13014.2002.
16. Tan W, Wang H, Chen Y, Zhang X, Zhu H, Yang C, Yang R, Liu C. 2011. Molecular aptamers for drug delivery. Trends Biotechnol. 29:634-640. http://dx.doi.org/10.1016/j.tibtech.2011.06.009.
17. Zhang Z, Zhao Z, Xu L, Wu X, Zhu H, Tan W, Fang X. 2011. Hepatitis C virus core protein detection by DNA aptamer. Scientia Sinica Chimica 41:1312-1318. http://dx.doi.org/10.1360/032011-198.
18. Yang D, Xue B, Wang X, Yu X, Liu N, Gao Y, Zhu H. 2013. 2-Octynoic acid inhibits hepatitis C virus infection through activation of AMPactivated protein kinase. PLoS One 8:e64932. http://dx.doi.org/10.1371/journal.pone.0064932.
19. Yang D, Liu N, Zuo C, Lei S, Wu X, Zhou F, Liu C, Zhu H. 2011. Innate immune response of primary human hepatocytes with hepatitis C viral infection. PLoS One 6:e27552. http://dx.doi.org/10.1371/journal.pone.0027552.
20. Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, Murayama A, Date T, Matsuura Y, Miyamura T, Wakita T, Suzuki T. 2008. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J. Virol. 82:7964-7976. http://dx.doi.org/10.1128/JVI.00826-08.
21. Counihan NA, Rawlison SM, Lindenbach BD. 2011. Trafficking of hepatitis C virus core protein during virus particle assembly. PLoS Pathog. 7:e1002302. http://dx.doi.org/10.1371/journal.ppat.1002302.
22. Dawson GJ. 2012. The potential role of HCV core protein antigen testing in diagnosing HCV infection. Antivir. Ther. 17:1431-1435. http://dx.doi.org/10.3851/IMP2463.
23. Lee S, Kim YS, Jo M, Jin M, Lee DK, Kim S. 2007. Chip-based detection of hepatitisCvirus usingRNAaptamers that specifically bind toHCVcore protein. Biochem. Biophys. Res. Commun. 358:47-52. http://dx.doi.org/10.1016/j.bbrc.2007.04.057.
24. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. 2011. Differential efficacy of protease inhibitors againstHCVgenotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant virus. Gastroenterology 141:1067-1079. http://dx.doi.org/10.1053/j.gastro.2011.06.004.
25. Halfon P, Locarnini S. 2011. Hepatitis C virus resistance to protease inhibitors. J. Hepatol. 55:192-206. http://dx.doi.org/10.1016/j.jhep.2011.01.011.
26. Shindo H, Maekawa S, Komase K, Sueki R, Miura M, Kadokura M, Shindo K. 2012. Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients. Hepatol. Int. 6:482-490. http://dx.doi.org/10.1007/s12072-011-9306-7.
27. Ramalingam D, Duclair S, Datta SAK, Ellington A, Rein A, Prasad VR. 2011. RNA aptamers directed to human immunodeficiency virus type 1 Gag protein bind to matrix and nucleocapsid domains and inhibit virus production. J. Virol. 85:305-314. http://dx.doi.org/10.1128/JVI.02626-09.
28. Ditzler MA, Bose D, Shkriabai N, Marchand B, Sarafiano SG, Kvaratskhelia G, Burke DH. 2011. Broad-spectrum aptamer inhibitors of HIV reverse transcriptase closely mimic natural substrates. Nucleic Acids Res.39:8237-8247. http://dx.doi.org/10.1093/nar/gkr381.
29. Hwang SY, Sun HY, Lee KH, Oh BH, Cha YJ, Kim BH, Yoo JY. 2012. 5-Triphosphate-RNA-independent activation of RIG-I via RNA aptamer with enhanced antiviral activity. Nucleic Acids Res. 40:2724-2733. http://dx.doi.org/10.1093/nar/gkr1098.
30. Bentham M, Holmes K, Forrest S, Rowlands DJ, Stonehouse NJ. 2012. Formation of higher-order foot-and-mouth disease virus 3Dpol complexes is dependent on elongation activity. J. Virol. 86:2371-2374. http://dx.doi.org/10.1128/JVI.05696-11.
31. Moore MD, Cookson J, Coventry VK, Sproat B, Rabe L, Cranston RD, McGowan I, James W. 2011. Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNAbased therapeutics. J. Biol. Chem. 286:2526-2535. http://dx.doi.org/10.1074/jbc.M110.178426.
32. Van Melckebeke H, Devany M, Di Primo C, Beaurain F, Toulme JJ, Bryce DL, Boisbouvier J. 2008. Liquid-crystal NMR structure of HIV TARRNAbound to its SELEXRNAaptamer reveals the origins of the high stability of the complex. Proc. Natl. Acad. Sci. U.S.A. 105:9210-9215. http://dx.doi.org/10.1073/pnas.0712121105.
33. Wheeler LA, Trifonova R, Vrbanac V, Basar E, McKernan S, Xu Z, Seung E, Deruaz M, Dudek T, Einarsson JI, Yang L, Allen TM, Luster AD, Tager AM, Dykxhoorn DM, Lieberman J. 2011. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using C4 aptamer-siRNA chimeras. J. Clin. Invest. 121:2401-2412. http://dx.doi.org/10.1172/JCI45876.